A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
Phase 3 Unknown
366 enrolled
CLOVER
Phase 3 Unknown
2,172 enrolled
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
Phase 3 Unknown
552 enrolled
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Phase 2 Unknown
68 enrolled
HIST-RIC
Phase 2 Unknown
101 enrolled
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
Phase NA Unknown
200 enrolled
easy laugh
Phase NA Unknown
204 enrolled
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Phase 3 Unknown
590 enrolled
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Phase 2 Unknown
100 enrolled
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
Phase 2 Unknown
59 enrolled
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
Phase 3 Unknown
1,871 enrolled
Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer
Phase 1 Unknown
30 enrolled
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Phase 2/3 Unknown
130 enrolled
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
Phase 3 Unknown
50 enrolled
IMMUN-HER
Phase 2 Unknown
65 enrolled
CAMELLIA
Phase 3 Unknown
280 enrolled
SOBER
Phase 2 Unknown
112 enrolled
Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer
Phase NA Unknown
100 enrolled
TENDENCY
Phase 2/3 Unknown
300 enrolled
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
Phase 3 Unknown
272 enrolled
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC
Phase 2 Unknown
79 enrolled
TNT
Phase 3 Unknown
400 enrolled
NeoChAI
Phase 2 Unknown
114 enrolled
ACCN
Phase 3 Unknown
120 enrolled
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Phase 2 Unknown
160 enrolled
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Phase 3 Unknown
300 enrolled
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Phase 2/3 Unknown
200 enrolled
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
Phase 3 Unknown
1,206 enrolled 19 charts
NNBC3-Europe
Phase 3 Unknown
4,150 enrolled
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Phase 2 Unknown
90 enrolled
Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Phase 3 Unknown
636 enrolled
TNM
Phase 2 Unknown
65 enrolled
PERS
Phase 3 Unknown
320 enrolled
PROMIX
Phase 2 Unknown
151 enrolled
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
Phase 2 Unknown
80 enrolled
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Phase NA Unknown
600 enrolled
Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase 4 Unknown
200 enrolled
A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs
Phase 2 Unknown
200 enrolled
Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer
Phase 2 Unknown
40 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
Phase 2 Unknown
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
Phase 3 Unknown
Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient
Phase 2 Unknown
49 enrolled
Combination Chemotherapy in Treating Women With Breast Cancer
Phase 3 Unknown
350 enrolled
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer
Phase 2 Unknown
42 enrolled
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
Phase 3 Unknown
2,500 enrolled
GORG-002
Phase 3 Unknown
260 enrolled
CBCRT01
Phase 3 Unknown
800 enrolled
NeoTG
Phase 2 Unknown
99 enrolled
STORM
Phase 2 Unknown
51 enrolled
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
Phase 3 Unknown
200 enrolled